Delirium is a serious mental disorder, which can cause two most common type of behaviors, namely, hyperactive behavior, which is characterized by severe confusion, disorientation and disturbance in consciousness that fluctuates and hypoactive behavior, which is characterized by the sudden onset of withdrawal from interaction with the outside world. This serious mental disorder is mainly caused due to physical or mental illnesses, which is temporary and reversible in most of the cases. Major symptoms include clouding of consciousness, disorientation of thoughts, illusions, hallucinations, fluctuating levels of consciousness, dysphasia, dysarthria, tremors, asterixis in hepatic encephalopathy and uremia. Some major factors that cause delirium are withdrawal from alcohol or sedatives, drug abuse, chemical disturbances within the body, infections, strokes, dementia, poisoning and surgeries.
Major driving factors for the growth of this market include, increasing prevalence of various neurological disorders worldwide, rising number of cases of physical and mental illnesses, increasing prevalence of cardiovascular diseases and rising demand for advanced therapeutics. The world is experiencing a shift in the population suffering from mental disorders, which is increasing at a rapid rate due to various factors like brain and heart related problems, related surgeries, alcohol or other drug abuse etc. These will help drive the demand for new and advanced therapeutics for delirium treatment. Thus, above factors will drive the growth of this market in future.
Geographically, North America dominates the delirium market followed by the European market. Some of the major factors responsible for these regions’ dominance are their high awareness levels about the disease and its available treatments and their affordability. However, Asia-Pacific is the most lucrative market as this region is showing the fastest growth due to increasing incidences of the disease and growing healthcare awareness as well. Some of the key players operating in this market are Air Liquide Sante International, Asklepios Kliniken GmbH, Dr. Franz Kohler Chemie GmbH, Fraser Health, Gaia BioPharma Ltd., Hospira, Inc., Novartis AG, Pfizer, Inc., andRegenstrief Institute, Inc.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments.